Key facts
- It has raised $17.0M; the latest was Seed Round ($8.7M) in Dec 2024.
- Notable investors include Endless Frontier Labs, Innovation Authority, AION Labs, AstraZeneca, Awz Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Promise Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Promise Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Promise Bio
Operator of an artificial intelligence-based healthcare platform intended to treat lingering diseases. The company specializes in harnessing complex artificial intelligence biomarker discovery technology to optimize personalized treatment plans and facilitate care, enabling patients to get affordable treatment for chronic diseases and improve their health.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2023
- Employees
- 13
- Website
- promise.bio/
- Ownership
- Privately Held (backing)
Promise Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Promise Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Promise Bio in its N-PORT filings yet. We sweep new filings monthly.